Frank Dolan

WuXi AppTec Faces US Revenue Decline for First Time in Five Years: Impacts of the Biosecure Act

WuXi AppTec Faces US Revenue Decline for First Time in Five Years: Impacts of the Biosecure Act

Frank Dolan March 17, 2025

UK Government's Controversial Move: Doubling Pharmaceutical Rebates Could Impact NHS Funding and Drug Prices

UK Government’s Controversial Move: Doubling Pharmaceutical Rebates Could Impact NHS Funding and Drug Prices

Frank Dolan March 14, 2025

Revolutionizing Parkinson's Treatment: MeiraGTx Partners with AI Startup Hologen to Enhance Gene Therapy Solutions

Revolutionizing Parkinson’s Treatment: MeiraGTx Partners with AI Startup Hologen to Enhance Gene Therapy Solutions

Frank Dolan March 13, 2025

Breakthroughs at CROI 2023: Merck and ViiV Healthcare's Innovative Advances in HIV Treatment

Breakthroughs at CROI 2023: Merck and ViiV Healthcare’s Innovative Advances in HIV Treatment

Frank Dolan March 12, 2025

Merck Triumphs in Court: Gardasil HPV Vaccine Risk Claims Dismissed by Judge

Merck Triumphs in Court: Gardasil HPV Vaccine Risk Claims Dismissed by Judge

Frank Dolan March 11, 2025

BioNTech's 2025 Revenue Forecast Sparks Investor Concerns and Stock Decline

BioNTech’s 2025 Revenue Forecast Sparks Investor Concerns and Stock Decline

Frank Dolan March 10, 2025

Bayer's Bold Move: Seeking Shareholder Approval for Billions in Equity to Tackle Monsanto Litigation Costs

Bayer’s Bold Move: Seeking Shareholder Approval for Billions in Equity to Tackle Monsanto Litigation Costs

Frank Dolan March 7, 2025

Reshoring Pharma Manufacturing: Why Bringing Production Back to the US is a 5-10 Year Journey

Reshoring Pharma Manufacturing: Why Bringing Production Back to the US is a 5-10 Year Journey

Frank Dolan March 6, 2025

FDA Takes Action Against Edenbridge Pharmaceuticals for Deceptive Hemady Advertising in Multiple Myeloma Treatment

FDA Takes Action Against Edenbridge Pharmaceuticals for Deceptive Hemady Advertising in Multiple Myeloma Treatment

Frank Dolan March 4, 2025

Biohaven Pharmaceuticals' Potassium Channel Drug Fails in Late-Stage Bipolar Mania Trial: Insights from Q4 Earnings Report

Biohaven Pharmaceuticals’ Potassium Channel Drug Fails in Late-Stage Bipolar Mania Trial: Insights from Q4 Earnings Report

Frank Dolan March 3, 2025

Pharmaceutical Giants Join Forces: Six Companies Ready for Medicare Price Negotiations Amid Legal Uncertainties

Pharmaceutical Giants Join Forces: Six Companies Ready for Medicare Price Negotiations Amid Legal Uncertainties

Frank Dolan February 28, 2025

Mission Therapeutics Shifts Focus: Ending Preclinical Operations to Advance MTX325 and MTX652

Mission Therapeutics Shifts Focus: Ending Preclinical Operations to Advance MTX325 and MTX652

Frank Dolan February 27, 2025

Regeneron Aims for Fast-Track Approval of Innovative T Cell Engager for Lymphoma Treatment

Regeneron Aims for Fast-Track Approval of Innovative T Cell Engager for Lymphoma Treatment

Frank Dolan February 26, 2025

2024 Biopharma Layoffs: Major Companies Slash Jobs Amid Industry Challenges

2024 Biopharma Layoffs: Major Companies Slash Jobs Amid Industry Challenges

Frank Dolan February 25, 2025

Boehringer Ingelheim Triumphs in Zantac Litigation: Illinois Jury Rules in Favor of Prostate Cancer Patients

Boehringer Ingelheim Triumphs in Zantac Litigation: Illinois Jury Rules in Favor of Prostate Cancer Patients

Frank Dolan February 25, 2025

Top Biotech and Pharma Stocks to Watch: Trends, Insights, and Investment Tips for 2023

Top Biotech and Pharma Stocks to Watch: Trends, Insights, and Investment Tips for 2023

Frank Dolan February 24, 2025

FDA CDRH Layoffs and Reinstatements: What You Need to Know

FDA CDRH Layoffs and Reinstatements: What You Need to Know

Frank Dolan February 24, 2025

2024 Biopharma Downfall: Major Layoffs and Facility Closures Shake the Industry

2024 Biopharma Downfall: Major Layoffs and Facility Closures Shake the Industry

Frank Dolan February 21, 2025

Teva and Alvotech Unveil Revolutionary Biosimilar of Stelara with 85% Price Slash: A Game Changer for Immunosuppressive Treatments!

Teva and Alvotech Unveil Revolutionary Biosimilar of Stelara with 85% Price Slash: A Game Changer for Immunosuppressive Treatments!

Frank Dolan February 21, 2025

Navigating the Turbulent Waters of Biotech: Opportunities Amidst Challenges Following Robert F. Kennedy Jr.'s Appointment

Navigating the Turbulent Waters of Biotech: Opportunities Amidst Challenges Following Robert F. Kennedy Jr.’s Appointment

Frank Dolan February 20, 2025

Stay up to date on the latest news

By pressing the Subscribe button, you confirm that you have read our Privacy Policy.

WuXi AppTec Faces US Revenue Decline for First Time in Five Years: Impacts of the Biosecure Act

WuXi AppTec Faces US Revenue Decline for First Time in Five Years: Impacts of the Biosecure Act

UK Government's Controversial Move: Doubling Pharmaceutical Rebates Could Impact NHS Funding and Drug Prices

UK Government’s Controversial Move: Doubling Pharmaceutical Rebates Could Impact NHS Funding and Drug Prices

First Timers Club: Biopharma Launches in 2025 and 2026

Email Us

info at arsenal-advisors.com

Headquarters

Cambridge, MA USA